Introduction
============

Cervical cancer is one of most common types of cancer; there are \~470,000 new cases and 233,000 associated mortalities per year worldwide ([@b1-ol-0-0-8494],[@b2-ol-0-0-8494]). The reported five-year survival rate is 68% in the United States ([@b3-ol-0-0-8494]) and patient outcomes depend on how early the cancer is detected ([@b4-ol-0-0-8494]). The occurrence rate is high, at \~70% in developing countries ([@b5-ol-0-0-8494]). In developed countries, the rate has been markedly reduced with the application of cervical screening programs ([@b5-ol-0-0-8494]). The greatest risk factor for cervical cancer is type 16 and 18 human papillomavirus (HPV) infection, which accounts for 75% of cervical cancer cases ([@b6-ol-0-0-8494]). Smoking is the next most significantly associated risk factor for cervical cancer; the incidence of invasive cervical cancer is 2--3 times higher in current or former smokers among HPV-infected women ([@b7-ol-0-0-8494]).

HPV infection is one of the most important causative molecular mechanisms for cervical cancer ([@b8-ol-0-0-8494]). The high-risk HPV types encode two oncoproteins, E6 and E7, which can inactivate tumor suppressor proteins and abrogate apoptosis ([@b8-ol-0-0-8494]). Using advanced microarray and next-generation sequencing technologies, researchers have explored the gene expression profile and molecular mechanisms of cervical cancer. In 2006, Wong *et al* ([@b9-ol-0-0-8494]) used oligonucleotide microarray analysis and reverse transcription-polymerase chain reaction to demonstrate that secreted phosphoprotein 1, cyclin dependent kinase inhibitor 2A (*CDKN2A*), ribosomal protein *L39* and *C1orf10* were differentially regulated in cervical cancer compared with normal cervix tissue. Connective tissue growth factor and regulator of G protein signaling 1 were identified as upregulated in late stage cervical cancer ([@b9-ol-0-0-8494]). The pelvic lymph node metastasis ability of early-stage cervical cancer has been associated with barrier to autointegration factor 1, La ribonucleoprotein domain family member 7, Secretory carrier membrane protein, CUE domain containing 1 and phosphatidylethanolamine binding protein 1 by comparing gene expression profiles of tumor samples from patients with and without metastasis ([@b10-ol-0-0-8494]).

Several critical microRNAs (miRs/miRNAs) have also been identified in cervical cancer. Hu *et al* ([@b11-ol-0-0-8494]) indicated that miR-200a and miR-9 can predict patient survival, and that miR-200 likely affects the metastatic process of cervical cancer cells by suppressing the genes controlling cell motility. The expression of miR-424 has been demonstrated as significantly downregulated in 147 cervical cancer tissues vs. 74 normal tissues ([@b12-ol-0-0-8494]). miR-424 has also been identified as a crucial tumor suppressor through the mechanism of upregulating the expression and phosphorylation of *CHEK1* ([@b12-ol-0-0-8494]).

Although various studies have explored the expression profiles of cervical cancer, a combination of mRNA and miRNA expression profiles has rarely been studied in cervical cancer. A large number of microarray expression datasets are publicly available in the Gene Expression Omnibus (GEO) database, and data-mining the deposited datasets using bioinformatics methods may advance the understanding of cervical cancer ([@b13-ol-0-0-8494]). In the present study, the significantly differentially expressed genes (DEGs) in cervical cancer were first identified based on two expression datasets from independent labs. DEGs were then subjected to functional annotation based on the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The regulation mechanisms between the identified DEGs and reported miRNAs in cervical cancer were then explored. The prognostic performance of the identified DEGs were virtually validated using the SurvExpress online database.

Materials and methods
=====================

### mRNA and miRNA expression profiles

Datasets for cervical cancer were obtained from the publicly available GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). Two mRNA expression profile datasets that used the same platform and contained normal tissue controls were selected. GSE63678 was submitted by Pappa *et al* in 2014 ([@b14-ol-0-0-8494]), and contains 5 normal tissues and 5 cancer tissues, whereas GSE63514 was submitted by den Boon *et al* in 2014 ([@b15-ol-0-0-8494]) and includes 24 normal tissue and 28 cancer tissue expression profiles. Both of these datasets had been produced using the Affymetrix Human Genome U133 Plus 2.0 array. Further information regarding the original samples and experiments are documented in the referenced manuscripts.

### Identification of differentially expressed genes

An R script and database produced in-house were used for the data analysis and annotation. In brief, mRNA expression profiles underwent background correction, normalization and log~2~ transformation with the GeneChip Robust Multi-array Analysis algorithm ([@b16-ol-0-0-8494]). Control probe sets were filtered out, and the mean expression was calculated for genes with multiple probes. Finally, the Linear Models for Microarray Analysis algorithm in Bioconductor was applied for DEG screening ([@b17-ol-0-0-8494]). The common DEGs between the two data sets were also identified. Criteria to indicate a statistically significant difference were set to P≤0.05 and absolute log~2~ (fold-change) ≥2.

### GO and KEGG pathway annotation

The identified DEGs were subjected to GO and KEGG pathway enrichment analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online ([@b18-ol-0-0-8494]). GO terms were identified in the Biological Process (BP), Cellular Component (CC) and Molecular Function (MF) categories. P\<0.05 was set as the significance threshold.

miRNAs may be critical in carcinogenesis and metastasis through their regulation of mRNA expression; by searching PubMed, 6 critical miRNAs involved in the development of cervical cancer were identified: miR-200a-5p, miR-9-5p, miR-424-5p, miR-133b, miR-224-3p and miR-506-5p ([@b11-ol-0-0-8494],[@b12-ol-0-0-8494],[@b19-ol-0-0-8494]--[@b21-ol-0-0-8494]). A regulation network between the common DEGs and 4 miRNAs was constructed. miRNA targets were predicted based on the microcosm ([@b22-ol-0-0-8494]), mirTarbase ([@b23-ol-0-0-8494]) and TargetScan ([@b24-ol-0-0-8494]) databases, and the associations between the common DEGs and the target genes were identified. Finally, the regulation network was plotted using CyTargetLinker plugin ([@b25-ol-0-0-8494]) in Cytoscape v3.5.1 ([@b26-ol-0-0-8494]).

### Co-expression and interaction network analysis

The concept of co-expression can be used for the identification of novel mechanisms that contribute to tumorigenesis and progression ([@b27-ol-0-0-8494]). To identify patterns of co-expression, the odds ratio (OR) between each pair of query genes was calculated, and significant pairs were selected based on the cervical carcinoma data ([@b28-ol-0-0-8494]) from The Cancer Genome Atlas (TCGA) ([@b28-ol-0-0-8494]) using cBioPortal ([@b29-ol-0-0-8494]). The interactions between the identified DEGs and potential cancer drug targets were predicted based on various databases, including Reactome ([@b30-ol-0-0-8494]), DrugBank ([@b31-ol-0-0-8494]), CancerRxGene ([@b32-ol-0-0-8494]) and PANTHER ([@b33-ol-0-0-8494]).

### In-silico validation

To validate the clinical significance of the identified DEGs, they were first validated in large cohort cervical cancer samples from TCGA ([@b28-ol-0-0-8494]) using cBioPortal ([@b30-ol-0-0-8494]). The prognostic performance of the 16 selected DEGs was then virtually evaluated using the SurvExpress database, which includes gene expression datasets with clinical outcome data ([@b34-ol-0-0-8494]). One cervical cancer dataset ([@b28-ol-0-0-8494]), including clinical information, was selected from TCGA for virtual validation. Detailed information regarding the dataset can be found in the original study ([@b28-ol-0-0-8494]). Parameters were carefully selected according to the developer\'s guide that provides optimized parameters ([@b34-ol-0-0-8494]). A heatmap for all samples, based on the miRNA target genes, was plotted using the heatmap module in Bioconductor ([@b35-ol-0-0-8494]).

Results
=======

### DEGs in cervical cancer

Subsequent to background correction and normalization, the median gene expression values for the two datasets were similar (data not shown). A total of 975 and 402 DEGs were screened in GSE63514 and GSE63678, respectively. In GSE63514, this included 523 upregulated (53.6%) and 452 downregulated genes (46.4%), and in GSE63678, 160 upregulated (39.8%) and 242 downregulated genes (60.2%). [Fig. 1](#f1-ol-0-0-8494){ref-type="fig"} illustrates that 92 common genes were differentially expressed between GSE63514 and GSE63678, and fold-changes for the top 20 up/downregulated common DEGs are listed in [Table I](#tI-ol-0-0-8494){ref-type="table"}.

### GO and KEGG pathway annotation

To identify the biological functions of the common DEGs, GO and KEGG pathway enrichment analysis were performed using the DAVID online tool. The results indicate that the common DEGs are significantly enriched in three KEGG pathways ([Table II](#tII-ol-0-0-8494){ref-type="table"}). A total of 10 genes were associated with 'cell cycle' P=9×10^−9^), 6 with 'p53 signaling' (P=2.2×10^−5^) and 5 genes with 'oocyte meiosis' (P=0.002). In GO terms, DEGs were most commonly associated with molecular functions of 'microtubule binding' (P=9.4×10^−5^), 'ATP binding' (P=1.7×10^−4^) and 'protein binding' (P=5.2×10^−4^; [Table III](#tIII-ol-0-0-8494){ref-type="table"}). The top 5 most significantly enriched terms in biological process were 'S transition of mitotic cell cycle' (P=8.3×10^−11^), 'cell division' (P=1.6×10^−9^), 'mitotic nuclear division' (P=4.5×10^−8^), 'G2/M transition of mitotic cell cycle' (P=4.3×10^−7^) and 'sister chromatid cohesion' (P=7.6×10^−7^; [Table III](#tIII-ol-0-0-8494){ref-type="table"}). The top 5 significantly enriched terms in cellular component were 'midbody' (P=2.4×10^−11^), 'nucleoplasm' (P=3.2×10^−11^), 'nucleus' (P=9.5×10^−10^), 'chromosome centromeric region' (P=8.9×10^−9^) and 'spindle microtubule' (P=5.7×10^−8^; [Table III](#tIII-ol-0-0-8494){ref-type="table"}).

### mRNA-miRNA network construction

The 6 identified miRNAs could target 231, 2,792 and 3,143 genes in the miRTarBase, MicroCosm and TargetScan databases, respectively. Among the target genes, 16 genes were common DEGs. Based on the interaction network between the 16 genes and 4 miRNAs ([Fig. 2](#f2-ol-0-0-8494){ref-type="fig"}), it was identified that miR-424-5p could regulate 5 genes, miR-9-5p could regulate 9 genes, miR-133b could regulate 4 genes and miR-200a-5p could regulate one gene. All samples from the two datasets were subjected to hierarchical clustering using the expression of the 16 DEGs. [Fig. 3](#f3-ol-0-0-8494){ref-type="fig"} illustrates that tumor (red) and normal (blue) samples can almost be classified into two groups. Data for a number of tumor and normal samples were confounded; this was most likely due to tumor heterogeneity or expression value variation.

### Co-expression and interaction network analysis

To reveal gene co-expression patterns, the significant gene pairings were selected based on odds ratio. This analysis identified 12 gene pairings among the 16 DEGs. SRY-box 17 (*SOX17*) tended to be co-expressed with paternally expressed 3 (*PEG3*), growth regulation by estrogen in breast cancer 1 (*GREB1*), inhibitor of DNA binding 4 (*ID4*) and Spondin 1 (*SPON1*), respectively (P\<0.01; [Table IV](#tIV-ol-0-0-8494){ref-type="table"}). *PEG3* was often co-expressed with *ID4* and *GREB1* (P\<0.05; [Table IV](#tIV-ol-0-0-8494){ref-type="table"}). In addition, the interaction network indicated that Checkpoint kinase 1 (*CHEK1*), Cyclin E2 (*CCNE2*), *CDKN2A* and Wings apart-like protein homolog interact via Transcription factor Dp-2, E2F transcription factor 1, Topoisomerase (DNA) II binding protein 1, *ATR* and karyopherin subunit α1 ([Fig. 4](#f4-ol-0-0-8494){ref-type="fig"}). Cancer drugs Roscovitine, AZD7762 and 681640 can target *CDKN2A* and *CHEK1* respectively ([Fig. 4](#f4-ol-0-0-8494){ref-type="fig"}).

### In-silico validation

In a large cohort of cervical cancer samples, the identified common DEGs were all differentially expressed (z-score, \<-2 or \>2). The percentage of sample ranged from 1.3 to 12% ([Fig. 5](#f5-ol-0-0-8494){ref-type="fig"}). The prognostic performance of the 16 genes was virtually validated using the SurvExpress online tool\'s cervical cancer dataset. This analysis indicated that low- and high-risk cervical cancer groups could be significantly differentiated based on the 16 genes ([Fig. 6](#f6-ol-0-0-8494){ref-type="fig"}). The low P-value (P=0.001) and high concordance index suggested that an accurate prediction of prognosis could be achieved based on the DEGs.

Discussion
==========

With the rapid development of microarray and NGS technologies, more and more cervical cancer molecular biomarkers have been identified. However, there has been limited integration of multi-omic data for the exploration of the molecular mechanisms of cervical cancer. In this study, mRNA expression profiles and previously identified miRNA-mRNA interactions were integrated to contribute to the characterization of the complex mechanism of cervical cancer. Systematic analysis revealed that 92 genes were simultaneously differentially expressed in 33 tumor tissues and that 16 DEGs may have been regulated by 4 critical miRNAs. The tumor and normal tissues were clearly classified into two groups based on the expression of the 16 DEGs.

Pathway enrichment analysis indicated that 6 DEGs were associated with 'p53 signaling'. The study by Xiao *et al* ([@b36-ol-0-0-8494]) indicated that *fra-1* was significantly downregulated in cervical cancer compared with adjacent normal tissue. *fra-1* can dysregulate p53 signaling via regulating the expression of *p53* and *MDM2 in vivo*.

Based on an mRNA-miRNA interaction network, the mechanism of cervical cancer was further characterized, indicating that miR-424-5p can regulate *CHEK1*. The protein encoded by this gene is required for checkpoint-mediated cell cycle arrest in response to DNA damage ([@b37-ol-0-0-8494]). Immunohistochemical study has indicated the ubiquitous expression of CHEK1 protein in cervical cancer, ovarian carcinoma and other types of cancer ([@b38-ol-0-0-8494]). In 2011, Mazumder *et al* ([@b39-ol-0-0-8494]) demonstrated that the deletion and methylation of CHEK1 were associated with the progression of cervical carcinoma, and that the inactivation of the *ATM-CHEK1* DNA damage response pathway participated in cervical cancer. ATM is activated by phosphorylation in response to DNA damage, which in turn activates its downstream target *CHEK1*, suggesting that inactivation of the *ATM-CHEK1*-associated DNA damage response pathway may have an important role in the development of cervical carcinoma ([@b39-ol-0-0-8494]). In addition, Xu *et al* ([@b12-ol-0-0-8494]) identified a critical tumor suppressive role for miR-424 in the progression of cervical cancer, at least partly via upregulating the expression of CHEK1 and p-CHEK1. Overexpression of miR-424 inhibited the expression of CHEK1 and p-CHEK1 at residue Ser345, and decreased the activity of the luciferase-reporter containing the 3′-untranslated region of CHEK1. Hsieh *et al* ([@b40-ol-0-0-8494]) revealed that *Euphorbia antiquorum* extracts could downregulate topoisomerase and activate ATM kinase, inducing the *CHEK1*/*2* and mitogen activated protein kinase signaling pathways, and promoting the degradation of cell division cycle 25A to induce S-phase arrest in HeLa cells.

An additional critical gene is *CDKN2A*, which may be regulated by miR-424-5p or miR-9-5p. *CDKN2A* encodes 2 main proteins, including p16INK4, which is a cyclin-dependent kinase inhibitor, and p14ARF, which can bind the p53-stabilizing protein MDM2 ([@b41-ol-0-0-8494]). These proteins participate in the regulation of two critical cell cycle regulatory pathways, the p53 pathway and the RB1 pathway. p16 can decelerate cell cycle progression from G1 phase to S phase. Wijetunga *et al* ([@b42-ol-0-0-8494]) reported a novel potential link between early cervical cancer disease progression and CpG-DNA methylation within the area 700 bp downstream of the transcriptional start site of *CDKN2A*, which may lead to increased p16INK4A/p14ARF expression prior to the development of malignant disease. In advanced cervical cancers, the majority of cells exhibited methylated *CDKN2A*, a lack of p16INK4A protein and no expression of HPV E7, suggesting p16INK4A inactivation may be a mechanism of blocking the cyclin D-RB1 pathway in invasive cervical cancer ([@b43-ol-0-0-8494]).

*SOX17* encodes a member of the SOX family involved in the regulation of embryonic development and the determination of cell fate, and can be regulated by miR-9-5p ([@b44-ol-0-0-8494]). *SOX17* methylation frequency has been reported to be significantly higher in squamous cell carcinoma than in cervical adenocarcinoma, indicating that *SOX17* silencing may contribute to the aberrant activation of Wnt signaling in cervical cancer ([@b45-ol-0-0-8494]). Furthermore, *SOX17* exhibited general hypermethylation in CpG sites analyzed in cervical cancer samples and may interact directly with *CTNNB1* ([@b46-ol-0-0-8494]). Genes previously unreported, to the best of our knowledge, including *CEP55* and *ID4*, were also identified in this study.

In summary, the development and progression of cervical cancer is likely to be induced by various processes. The present study identified DEGs that may be potential targets for regulation in cervical cancer.

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81373075, 8167140, 81371748 and 81571395).

![Venn diagram illustrating the differentially expressed genes identified in GSE63514 and GSE63678, and those common between the datasets.](ol-15-06-8965-g00){#f1-ol-0-0-8494}

![Regulation network of the 16 common deferentially expressed genes (pink hexagons) and the 4 documented microRNAs (green circles). The edge color represents the interaction information source. Red, miRTarBase; blue, MicroCosm; purple, TargetScan.](ol-15-06-8965-g01){#f2-ol-0-0-8494}

![Heat map illustrating the different expression patterns of the 16 differentially expressed genes in all samples. The x-axis represents individual samples and the y-axis represents genes. The top bar indicates the tumor samples (red) and the normal samples (blue).](ol-15-06-8965-g02){#f3-ol-0-0-8494}

![Interaction network between the identified differentially expressed genes and potential drugs. Each node is color coded along a white to red color gradient, indicating the total frequency of alteration across the selected case set, the deeper the red, the higher the frequency of alteration). The hexagons represent a drug and the circles represent a gene. Node border: Thin, linker nodes or targets of DEGs; thick, selected DEGs. Edge colors: Blue, controls state change of; brown, controls transport of; green, controls expression of; yellow, controls phosphorylation of. DEGs, differentially expressed genes.](ol-15-06-8965-g03){#f4-ol-0-0-8494}

![Expression of the identified differentially expressed genes in large cohorts of cervical cancer samples.](ol-15-06-8965-g04){#f5-ol-0-0-8494}

![Kaplan-Meier curves for high- and low-risk groups, represented with red and green curves respectively, of a cervical cancer dataset in the SurvExpress database. Censored samples are marked with '+'. The red and green numbers on the x-axis represent the number of mortalities of high- and low-risk individuals, respectively, occurring prior to the end of follow-up. The number of samples, censored number and CI are displayed in the top-right insets. The red and green numbers below the x-axis represent the number of low- and high-risk patients alive. CI, concordance index.](ol-15-06-8965-g05){#f6-ol-0-0-8494}

###### 

Top 20 differentially expressed genes in the GSE63514 and GSE63678 datasets.

               Fold-change   
  ------------ ------------- ------
  *C1orf116*   −2.57         2.17
  *CEACAM6*    −2.05         3.32
  *BIRC5*      2.10          2.14
  *CCNB1*      2.11          2.45
  *CENPF*      2.27          2.18
  *AURKA*      2.31          2.43
  *BUB1B*      2.37          2.06
  *CDKN3*      2.41          2.20
  *CHEK1*      2.44          2.12
  *CEP55*      2.50          2.51
  *ASPM*       2.55          2.77
  *APOBEC3B*   2.58          2.06
  *CENPN*      2.63          2.02
  *CDK1*       2.68          2.35
  *CCNE2*      2.75          2.56
  *CENPE*      2.98          2.06
  *CDC7*       3.00          2.54
  *ATAD2*      3.59          2.36
  *CA9*        4.19          2.39
  *CDKN2A*     6.41          2.46

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment results for the common differentially expressed genes.

  Term                              P-value       Genes
  --------------------------------- ------------- ----------------------------------------------------------------------
  hsa04110: cell cycle              9.02×10^−9^   *CDKN2A, CDC7, MCM2, CDK1, CCNE2, CHEK1, BUB1B, CCNB1, MAD2L1, MCM4*
  hsa04115: p53 signaling pathway   2.20×10-5     *CDKN2A, CDK1, CCNE2, RRM2, CHEK1, CCNB1*
  hsa04114: oocyte meiosis          0.00234       *CDK1, AURKA, CCNE2, MAD2L1, PGR*

###### 

Top 5 GO terms for the common differentially expressed genes.

  A, Molecular function                                                          
  ----------------------- --------------------------------------- -------------- ------------------------------------------------------------------
  GO:0008017              microtubule binding                     9.49×10^−5^    *KIF4A, PRC1, CENPE, KIF11, KIF20A, BIRC5, CRYAB, NUSAP1*
  GO:0005524              ATP binding                             1.72×10^−^4    *ATAD2, KIF4A, CDC7, OAS2, FGFR2*
  GO:0005515              protein binding                         5.28×10^−4^    *CDKN2A, DTL, KIF4A, UBD, PGR*
  GO:0019901              protein kinase binding                  7.13×10-4      *CDKN2A, PRC1, AURKA, FOXM1, CCNE2, KIF11, KIF20A, CCNB1, KRT17*
  GO:0003777              microtubule motor activity              7.33×10^−4^    *KIF4A, CENPE, KIF2C, KIF11, KIF20A*
                                                                                 
  B, Biological process                                                          
                                                                                 
  ID                      GO Term                                 P-value        Genes
                                                                                 
  GO:0000082              G1/S transition of mitotic cell cycle   8.32×10-11     *CDKN2A, CDC7, MCM2, CDKN3, ID4*
  GO:0051301              cell division                           1.66×10^−9^    *CDC7, SMC4, CDK1, CCNB1, MAD2L1*
  GO:0007067              mitotic nuclear division                4.57×10-8      *CDK1, AURKA, NEK2, CEP55, BIRC5*
  GO:0000086              G2/M transition of mitotic cell cycle   4.38×10^−7^    *MELK, CDK1, HMMR, AURKA, NEK2, FOXM1, CHEK1, BIRC5, CCNB1*
  GO:0007062              sister chromatid cohesion               7.67×10-7      *CENPE, CENPN, CENPF, SLC35F6, KIF2C, BUB1B, BIRC5, MAD2L1*
                                                                                 
  C, Cellular component                                                          
                                                                                 
  ID                      GO Term                                 P-value        Genes
                                                                                 
  GO:0030496              midbody                                 2.49×10^−11^   *KIF4A, ECT2, PRC1, CEP55, BIRC5*
  GO:0005654              nucleoplasm                             3.29×10-11     *ATAD2, CDKN2A, DTL, SOX17, PGR*
  GO:0005634              nucleus                                 9.58×10^−10^   *ATAD2, CDKN2A, DTL, SOX17, PGR*
  GO:0000775              chromosome, centromeric region          8.95×10-9      *CENPE, CENPN, MKI67, CENPF, SLC35F6, KIF2C, OIP5, BIRC5*
  GO:0005876              spindle microtubule                     5.70×10^−8^    *KIF4A, PRC1, CDK1, AURKA, KIF11, BIRC5, NUSAP1*

GO, Gene Ontology; ATP, adenosine triphosphate.

###### 

The significant gene co-expression pairs among the differentially expressed genes.

  Gene A     Gene B       P-value   Log odds ratio
  ---------- ------------ --------- ----------------
  *SOX17*    *PEG3*       \<0.001   \>3
  *SOX17*    *GREB1*      \<0.001   \>3
  *SOX17*    *ID4*        \<0.001   \>3
  *SOX17*    *SPON1*      \<0.001   \>3
  *PEG3*     *GREB1*      \<0.001   \>3
  *PEG3*     *ID4*        0.023     2.759
  *GREB1*    *ID4*        0.007     2.521
  *CDKN2A*   *OIP5*       0.011     1.858
  *KIF2C*    *CCNE2*      0.004     1.709
  *CDKN2A*   *APOBEC3B*   0.030     1.475
  *CCNE2*    *PRC1*       0.035     1.243
  *CHEK1*    *APOBEC3B*   0.041     1.208
